IgFUS: What Does the Future Hold? A Conversation With Neal F. Kassell, MD
Executive SummaryTo gain some perspective on the current state of focused ultrasound research, Medtech Insight interviews Neal F. Kassell, MD, Chairman of the Focused Ultrasound Surgery Foundation and Distinguished Professor of Neurosurgery at the University of Virginia. Kassell outlines some of the successes and remaining challenges in this field, discusses research efforts supported by the Foundation, and provides his perspective on the wide-ranging impact this technology could have on future treatment paradigms across multiple specialties.
You may also be interested in...
Civica Rx has won an investment of $55m through a deal with the Blue Cross Blue Shield Association of US health insurance firms to create a new subsidiary that will acquire and develop generic filings to be launched in the US from 2022.
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.